Dukem Bio Merges with Subsidiary Radio D&S Labs
CTO Oh Seungjoon Appointed
Integration of R&D, Production, and Regulatory Approval
Enhanced RPT Development Capabilities
Full-scale Launch of CDMO Business
Accelerating RPT New Drug Development
Dukem Bio announced on the 23rd that it has decided to merge with its subsidiary, Radio D&S Labs. Along with the merger, Dr. Oh Seungjoon, founder of Radio D&S Labs, has been appointed as Chief Technology Officer (CTO).
Radio D&S Labs is an R&D-focused company specializing in radiopharmaceuticals and nuclear medicine imaging technology. Dukem Bio acquired all shares of Radio D&S Labs in 2024 and incorporated it as a subsidiary. Through this merger, the company plans to integrate its capabilities in candidate substance and imaging technology development, production, regulatory approval, and overall operations.
The company explained that the merger and the CTO appointment were decided to accelerate the development of its Contract Development and Manufacturing Organization (CDMO) business for radiopharmaceuticals. Dukem Bio also announced plans to expedite the development of new therapeutic radiopharmaceuticals (RPT), which it is jointly pursuing with Radio D&S Labs.
CTO Oh was responsible for obtaining new drug approval for the radiopharmaceutical '18F-FP-CIT' for the diagnosis of Parkinson's disease in 2008 and for the development of '18F-FES' for the diagnosis of recurrent and metastatic breast cancer in 2019. He also co-registered the original patent for an artificial intelligence (AI) early image prediction technology that forecasts later PET scan images using only initial scan data, and completed the U.S. patent registration for this technology this year. Dukem Bio is now working toward its commercialization.
Hot Picks Today
Karina Fetches 6.7 Billion Won, Lives Under 24-Hour Armed Guard... World's Most Expensive Cow in the Spotlight
- "If It Breaks, That's It": Chaos Among Samsung and SK hynix Consumers... Soaring SSD Prices Mean "No Replacement, Only Refund at Original Price"
- "I'll Pay with Both Shares and Cash" vs "Cash Only"... Why Chey Taewon Filed a Further Appeal After Careful Deliberation
- Yu In-chon: "Even Sadder Than Last Year"...Bicycle Pilgrimage to Mark Brother's First Anniversary
- Do Night Runners Need Sunscreen? MFDS Says "UV from Streetlights Has Minimal Impact"
Sangwoo Kim, CEO of Dukem Bio, said, "With CTO Oh joining, we have established CDMO capabilities to seamlessly conduct everything from candidate substance development to regulatory approval," and added, "We will strengthen our competitiveness in the CDMO business to match the global expansion of the RPT market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
